Browse > Article
http://dx.doi.org/10.5483/BMBRep.2013.46.1.123

Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells  

Kim, Nam-Hoon (Department of Medical Lifescience, College of Medicine, The Catholic University of Korea)
Park, Hyo Jung (Department of Medical Lifescience, College of Medicine, The Catholic University of Korea)
Oh, Mi-Kyung (Department of Medical Lifescience, College of Medicine, The Catholic University of Korea)
Kim, In-Sook (Department of Medical Lifescience, College of Medicine, The Catholic University of Korea)
Publication Information
BMB Reports / v.46, no.1, 2013 , pp. 59-64 More about this Journal
Abstract
Signal transducer and activator of transcription 3 (STAT3) and telomerase are considered attractive targets for anticancer therapy. The in vitro anticancer activity of the gold(I) compound auranofin was investigated using MDA-MB 231 human breast cancer cells, in which STAT3 is constitutively active. In cell culture, auranofin inhibited growth in a dose-dependent manner, and N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species (ROS), markedly blocked the effect of auranofin. Incorporation of 5-bromo-2'-deoxyuridine into DNA and anchorage-independent cell growth on soft agar were decreased by auranofin treatment. STAT3 phosphorylation and telomerase activity were also attenuated in cells exposed to auranofin, but NAC pretreatment restored STAT3 phosphorylation and telomerase activity in these cells. These findings indicate that auranofin exerts in vitro antitumor effects in MDA-MB 231 cells and its activity involves inhibition of STAT3 and telomerase. Thus, auranofin shows potential as a novel anticancer drug that targets STAT3 and telomerase.
Keywords
Antiproliferation; Auranofin; MDA-MB 231 cells; STAT3; Telomerase;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Komeda, S. and Casini, A. (2012) Next-generation anticancer metallodrugs. Curr. Top. Med. Chem. 12, 219-235.   DOI
2 Ott, I. and Gust, R. (2007) Non platinum metal complexes as anti-cancer drugs. Arch. Pharm. Chem. Life Sci. 340, 117-126.   DOI   ScienceOn
3 Borg, G., Allander, E., Lund, B., Berg, E., Brodin, U., Pettersson, H. and Trang, L. (1988) Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J. Rheumatol. 15, 1747-1754.
4 Kean, W. F. and Kean, I. R. (2008) Clinical pharmacology of gold. Inflammopharmacology 16, 112-125.   DOI   ScienceOn
5 Jeon, K. I., Byun, M. S. and Jue, D. M. (2003) Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med. 35, 61-66.   DOI   ScienceOn
6 Angelucci, F., Sayed, A. A., Williams, D. L., Boumis, G., Brunori, M., Dimastrogiovanni, D., Miele, A. E., Pauly, F. and Bellelli, A. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284, 28977-28985.   DOI   ScienceOn
7 Gromer, S., Arscott, L. D., Williams, C. H. Jr., Schirmer, R. H. and Becker, K. (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273, 20096-20101.   DOI   ScienceOn
8 Mustacich, D. and Powis, G. (2000) Thioredoxin reductase. Biochem. J. 346(Pt 1), 1-8.   DOI   ScienceOn
9 Biaglow, J. E. and Miller, R. A. (2005) The thioredoxin reductase/ thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. 4, 6-13.   DOI   ScienceOn
10 Powis, G. and Kirkpatrick, D. L. (2007) Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7, 392-397.   DOI   ScienceOn
11 Urig, S. and Becker, K. (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16, 452-465.   DOI   ScienceOn
12 Rigobello, M. P., Scutari, G., Folda, A. and Bindoli, A. (2004) Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 67, 689-696.   DOI   ScienceOn
13 Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Bjornstedt, M., Bindoli, A., Sturaro, A., Rella, R. and Marzano, C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101.   DOI   ScienceOn
14 Kim, I. S., Jin, J. Y., Lee, I. H. and Park, S. J. (2004) Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br. J. Pharmacol. 142, 749-755.   DOI   ScienceOn
15 Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A. and Messori, L. (2010) Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev. 30, 550-580.
16 Park, S. J. and Kim, I. S. (2005) The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol. 146, 506-513.   DOI   ScienceOn
17 Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872-881.   DOI   ScienceOn
18 Tiekink, E. R. (2008) Anti-cancer potential of gold complexes. Inflammopharmacology 16, 138-142.   DOI   ScienceOn
19 Hirano, T., Ishihara, K. and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556.   DOI
20 Chen, Z. and Han, Z. C. (2008) STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 28, 185-200.   DOI   ScienceOn
21 Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A. and Jove, R. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.   DOI   ScienceOn
22 Su, F., Ren, F., Rong, Y., Wang, Y., Geng, Y., Feng, M., Ju, Y., Li, Y., Zhao, Z. J., Meng, K. and Chang, Z. (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 14, R38.   DOI   ScienceOn
23 Nakaya, A., Sagawa, M., Muto, A., Uchida, H., Ikeda, Y. and Kizaki, M. (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk. Res. 35, 243-249.   DOI   ScienceOn
24 Konnikova, L., Simeone, M. C., Kruger, M. M., Kotecki, M. and Cochran, B. H. (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 65, 6516-6520.   DOI   ScienceOn
25 Lavecchia, A., Di Giovanni, C. and Novellino, E. (2011) STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem. 18, 2359-2375.   DOI   ScienceOn
26 Kim, N. H., Lee, M. Y., Park, S. J., Choi, J. S., Oh, M. K. and Kim, I. S. (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122, 607-614.   DOI   ScienceOn
27 Dixit, D., Sharma, V., Ghosh, S., Koul, N., Mishra, P. K. and Sen, E. (2009) Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med. 47, 364-374.   DOI   ScienceOn
28 Watson, W. H., Heilman, J. M., Hughes, L. L. and Spielberger, J. C. (2008) Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem. Biophys. Res. Commun. 368, 832-836.   DOI   ScienceOn